Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Sampling Compared for Leishmaniasis Rapid Test

By LabMedica International staff writers
Posted on 11 Jul 2013
Antibody-detecting rapid diagnostic tests (RDTs) are available to aid in the diagnosis of visceral leishmaniasis (VL), the second most fatal parasitic disease after malaria. More...


Although these RDTs have been developed, validated, and approved for use with serum, they are universally performed using whole blood and therefore it was deemed necessary to determine whether an established RDT is as sensitive on whole blood as on serum.

Tropical medicine specialists at McGill University (Montreal, QC, Canada) working with colleagues at the Rajendra Memorial Research Institute of Medical Sciences (Patna, India) compared serum and blood samples from 624 individuals with symptoms of VL attending the outpatient clinic. They used the rK39 immunochromatographic RDT to assess and evaluate the blood and serum samples from each patient. The test was considered positive when both the control line and the test line appeared red in color.

The rK39 Kalazar Detect RTD (InBios International; USA; Seattle, WA, USA) detected 251 cases who were seropositive on both blood and serum sample. In comparison, 334 were negative on both serum and blood. Notably, there were 26 cases that were negative on blood and positive on serum. These 26 individuals in general had low titer antibodies against rK39 as determined by an enzyme linked immunosorbent assay (ELISA) and follow-up on most of these individuals revealed none had persistent VL symptoms. There were 13 cases that were positive on blood and negative on serum and these were considered to be false positives.

The authors concluded that the major observation from their study was that the concordance of the rK39 RDT performed on serum versus blood was excellent. The test can however be negative on blood and positive on serum when the titer of anti-K39 antibodies is low. We therefore recommend that when an individual from an endemic area has clinical symptoms of VL and the blood rK39 RDT is negative, that the test should be redone two to three weeks later if the symptoms persist since during this interval the titer may increase if the disease begins to progress. The study was published on May 23, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
McGill University
Rajendra Memorial Research Institute of Medical Sciences
InBios International


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.